The FDA’s Oncologic Drugs Advisory Committee voted 8-0 against a new indication for Pfizer’s Talzenna in combination with Xtandi for first-line treatment of adults with non-homologous recombination repair mutated (non-HRRm) metastatic castration-resistant prostate cancer. ...
↧